<DOC>
	<DOCNO>NCT01945294</DOCNO>
	<brief_summary>The purpose study estimate difference efficacy 16-week treatment regimen boceprevir ( BOC ) combination peg-intron alpha 2b ( P ) plus ribavirin ( R ) ( BOC + PR ) 28-week treatment regimen BOC + PR previously untreated participant chronic hepatitis C ( CHC ) genotype 1 Asia achieve undetectable hepatitis C virus ribonucleic acid ( HCV RNA ) .</brief_summary>
	<brief_title>Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron Ribavirin Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 ( MK-3034-107 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>weigh ≥ 40 kg ≤ 125 kg CHC genotype 1 infection liver biopsy noninvasive liver fibrosis test show evidence cirrhosis hepatocellular carcinoma must agree participant participant 's partner use acceptable method contraception least 2 week prior Day 1 continue least 6 month last dose study medication , longer dictate local regulation ( female participant childbearing potential male participant female sexual partner childbearing potential ) participate interventional clinical trial within 30 day screen visit trial intend participate another interventional clinical trial participation trial coinfected human immunodeficiency virus ( HIV ) hepatitis B virus evidence history chronic hepatitis cause HCV , include limited nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis evidence decompensated liver disease include , limited , history presence clinical ascites , bleed varix , hepatic encephalopathy evidence hepatocellular carcinoma ( HCC ) evaluation HCC evidence active suspected malignancy , history malignancy , within last 5 year previously treat interferon ribavirin regimen HCV direct act antiviral regimen , treat hepatitis C investigational medication taking/plans take significant inducer inhibitor Cytochrome P450 3A4 ( CYP3A4 ) substrates 2 week prior start study medication , herbal supplement , include limited St. John 's Wort 2 week prior start study medication ( Day 1 ) preexist psychiatric condition ( ) clinical diagnosis substance abuse know medical condition could interfere participation completion trial include immunologicallymediated disease , chronic pulmonary disease , current history clinically significant cardiac abnormalities/dysfunction pregnant nursing ( female participant ) female partner intend become pregnant ( male participant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>